Ayretrade Inc (SUMM) 0.0610 $SUMM
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and C. difficile infection ('CDI', today reports its financial results for the first quarter ended 30 April 2016.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 8.61 (+0.06)
Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US.
SMMT: 8.61 (+0.06)
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and C. difficile infection ('CDI', today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016.
SMMT: 8.61 (+0.06)
Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015.
SMMT: 8.61 (+0.06)
Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection ('CDI', announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office.
SMMT: 8.61 (+0.06)
Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 8.61 (+0.06)
Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces the presentation today of major findings from the Phase 2 CoDIFy trial highlighting the potential of ridinilazole in the treatment of CDI at the 26 European Congress of Clinical Microbiology and Infectious Diseases ('ECCMID'. These findings include a markedly reduced recurrence rate and a statistically superior rate of sustained clinical response ('SCR' in patients with CDI receiving ridinilazole compared with those receiving the standard of care, vancomycin. Ridinilazole is a novel class antibiotic with the potential for broad use across the CDI disease spectrum.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company's 15 Annual Healthcare Conference, 13 April 2016 at 11:20am EDT in New York City.
SMMT: 8.61 (+0.06)
Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces positive interim data from a Phase 1 clinical trial evaluating a new oral formulation of its lead utrophin modulator, SMT C1100, for DMD. In this dose escalating clinical trial's initial dosing period, all patients achieved plasma drug levels within the range believed to be necessary for a potential therapeutic benefit. The initial dose tested of the new formulation was one tenth of that required with the current formulation of SMT C1100 to achieve similar drug concentration levels in the recent Phase 1b modified diet clinical trial of SMT C1100.
SMMT: 8.61 (+0.06)
Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
GlobeNewswire - Tue Mar 29, 8:25AM CDT
-- Data to be Presented at 26 ECCMID Conference, 11 April 2016
SMMT: 8.61 (+0.06)
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
GlobeNewswire - Tue Mar 15, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces the online publication on the development of imaging techniques designed to quantify utrophin protein and muscle fibre regeneration in muscle biopsies from patients with DMD and Becker muscular dystrophy ('BMD'.
SMMT: 8.61 (+0.06)
Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
GlobeNewswire - Mon Mar 07, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces additional positive data from the CoDIFy Phase 2 clinical trial that show the narrow spectrum antibiotic ridinilazole preserves the gut microbiome in CDI patients while the standard of care, vancomycin, inflicts substantial and long-lasting damage on the gut microbiome.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 8.61 (+0.06)
Summit Financial Group Reports Fourth Quarter and Full Year 2015 Results
GlobeNewswire - Mon Jan 25, 5:00AM CST
Summit Financial Group, Inc. ("Company" or "Summit" (NASDAQ:SMMF) today reported fourth quarter 2015 net income applicable to common shares of $4.15 million, or $0.39 per diluted share, compared to $3.01 million, or $0.32 per diluted share, for the fourth quarter of 2014, representing an increase of 37.8 percent, or 21.9 percent per diluted share. Q4 2015 earnings compared to Q4 2014 were positively impacted by a $782,000 increase in net interest income and a $314,000 gain on sale of foreclosed properties, but were negatively impacted by a $336,000 increase in write-downs of foreclosed properties and a $250,000 provision for loan losses compared to zero for Q4 2014.
SMMF: 16.62 (-0.48)
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles.
SMMT: 8.61 (+0.06)
Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI', announces that the European Patent Office ('EPO' has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile.
SMMT: 8.61 (+0.06)
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
GlobeNewswire - Thu Dec 17, 6:00AM CST
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and C. difficile infection ('CDI', today reports its financial results for the third quarter ended 31 October 2015.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015
GlobeNewswire - Mon Dec 14, 6:00AM CST
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its third quarter financial results for the period ending 31 October 2015 on Thursday, 17 December 2015.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Participate in the JMP Securities DMD Forum
GlobeNewswire - Thu Dec 10, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD' and Clostridium difficile infection, announces that the Company will participate in the JMP Securities DMD Forum on Monday, 14 December 2015 in New York City. The day will focus on the key themes and trends in DMD and feature discussions with publicly traded and privately held biopharmaceutical companies developing DMD therapies, including Summit's utrophin modulator programme. Utrophin modulation is a potential disease modifying approach that aims to treat all patients with this muscle-wasting disease.
SMMT: 8.61 (+0.06)
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and C. difficile infection ('CDI', today reports its financial results for the first quarter ended 30 April 2016. SMMT: 8.61 (+0.06)
Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
GlobeNewswire - Tue May 31, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2016 on Thursday, 2 June 2016.
SMMT: 8.61 (+0.06)
Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
GlobeNewswire - Mon May 23, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'
, announces that the Company will present additional positive Phase 2 CoDIFy trial data on ridinilazole versus standard of care, vancomycin, highlighting ridinilazole's preservation of the microbiome in the treatment of CDI. These data will be presented as posters at the ASM Microbe 2016 meeting that will be held 16-20 June in Boston, MA, US. SMMT: 8.61 (+0.06)
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Tue May 10, 6:07AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and C. difficile infection ('CDI', today reports its financial results for the fourth quarter and fiscal year ended 31 January 2016. SMMT: 8.61 (+0.06)
Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
GlobeNewswire - Fri May 06, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'
, will be announcing its financial results for the fourth quarter and fiscal year ended 31 January 2016 on Tuesday, 10 May 2015. SMMT: 8.61 (+0.06)
Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and Clostridium difficile infection ('CDI', announces the strengthening of the intellectual property estate protecting ridinilazole following the grant of a composition of matter patent by the United States Patent and Trademark Office. SMMT: 8.61 (+0.06)
Summit's IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the US
GlobeNewswire - Tue Apr 26, 6:02AM CDT
-- Enrolment of Patients with DMD in the US Expected to Start 3Q 2016
SMMT: 8.61 (+0.06)
Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'
, announces the presentation today of major findings from the Phase 2 CoDIFy trial highlighting the potential of ridinilazole in the treatment of CDI at the 26 European Congress of Clinical Microbiology and Infectious Diseases ('ECCMID'. These findings include a markedly reduced recurrence rate and a statistically superior rate of sustained clinical response ('SCR' in patients with CDI receiving ridinilazole compared with those receiving the standard of care, vancomycin. Ridinilazole is a novel class antibiotic with the potential for broad use across the CDI disease spectrum. SMMT: 8.61 (+0.06)
Summit Therapeutics to Present at 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at Needham & Company's 15 Annual Healthcare Conference, 13 April 2016 at 11:20am EDT in New York City.
SMMT: 8.61 (+0.06)
Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
GlobeNewswire - Wed Mar 30, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and Clostridium difficile infection, announces positive interim data from a Phase 1 clinical trial evaluating a new oral formulation of its lead utrophin modulator, SMT C1100, for DMD. In this dose escalating clinical trial's initial dosing period, all patients achieved plasma drug levels within the range believed to be necessary for a potential therapeutic benefit. The initial dose tested of the new formulation was one tenth of that required with the current formulation of SMT C1100 to achieve similar drug concentration levels in the recent Phase 1b modified diet clinical trial of SMT C1100. SMMT: 8.61 (+0.06)
Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole's Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile Infection
GlobeNewswire - Tue Mar 29, 8:25AM CDT
-- Data to be Presented at 26 ECCMID Conference, 11 April 2016
SMMT: 8.61 (+0.06)
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
GlobeNewswire - Tue Mar 15, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and Clostridium difficile infection, announces the online publication on the development of imaging techniques designed to quantify utrophin protein and muscle fibre regeneration in muscle biopsies from patients with DMD and Becker muscular dystrophy ('BMD'. SMMT: 8.61 (+0.06)
Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
GlobeNewswire - Mon Mar 07, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'
, announces additional positive data from the CoDIFy Phase 2 clinical trial that show the narrow spectrum antibiotic ridinilazole preserves the gut microbiome in CDI patients while the standard of care, vancomycin, inflicts substantial and long-lasting damage on the gut microbiome. SMMT: 8.61 (+0.06)
Summit Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 03, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18 Annual BIO CEO & Investor Conference, 9 February 2016 at 11:00am EST in New York City.
SMMT: 8.61 (+0.06)
Summit Financial Group Reports Fourth Quarter and Full Year 2015 Results
GlobeNewswire - Mon Jan 25, 5:00AM CST
Summit Financial Group, Inc. ("Company" or "Summit"
(NASDAQ:SMMF) today reported fourth quarter 2015 net income applicable to common shares of $4.15 million, or $0.39 per diluted share, compared to $3.01 million, or $0.32 per diluted share, for the fourth quarter of 2014, representing an increase of 37.8 percent, or 21.9 percent per diluted share. Q4 2015 earnings compared to Q4 2014 were positively impacted by a $782,000 increase in net interest income and a $314,000 gain on sale of foreclosed properties, but were negatively impacted by a $336,000 increase in write-downs of foreclosed properties and a $250,000 provision for loan losses compared to zero for Q4 2014. SMMF: 16.62 (-0.48)
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
GlobeNewswire - Thu Jan 21, 6:11AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and Clostridium difficile infection, announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency and the Research Ethics Committee to initiate PhaseOut DMD, a Phase 2 proof of concept clinical trial of SMT C1100 in patients with DMD. SMT C1100 is an orally administered, small molecule utrophin modulator that the Company believes has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. Utrophin is functionally and structurally similar to dystrophin, a protein which is essential for the healthy function of muscles. SMMT: 8.61 (+0.06)
Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile Infection
GlobeNewswire - Tue Jan 19, 6:16AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'
, announces that the European Patent Office ('EPO' has granted a key patent covering the novel antibiotic, ridinilazole, and that the opposition period has expired with the patent having faced no challenge. The patent covers the use of ridinilazole for the treatment of infections caused by the bacterium Clostridium difficile. SMMT: 8.61 (+0.06)
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
GlobeNewswire - Thu Dec 17, 6:00AM CST
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and C. difficile infection ('CDI', today reports its financial results for the third quarter ended 31 October 2015. SMMT: 8.61 (+0.06)
Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015
GlobeNewswire - Mon Dec 14, 6:00AM CST
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its third quarter financial results for the period ending 31 October 2015 on Thursday, 17 December 2015.
SMMT: 8.61 (+0.06)
Summit Therapeutics to Participate in the JMP Securities DMD Forum
GlobeNewswire - Thu Dec 10, 6:00AM CST
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'
and Clostridium difficile infection, announces that the Company will participate in the JMP Securities DMD Forum on Monday, 14 December 2015 in New York City. The day will focus on the key themes and trends in DMD and feature discussions with publicly traded and privately held biopharmaceutical companies developing DMD therapies, including Summit's utrophin modulator programme. Utrophin modulation is a potential disease modifying approach that aims to treat all patients with this muscle-wasting disease. SMMT: 8.61 (+0.06)
